Apixaban reduces stroke rates in atrial fibrillation patients with previous stroke or TIA

In a subset of patients that had experienced a previous stroke or transient ischemic attack (TIA), treatment with the investigational drug apixaban resulted in a reduced rate of stroke and systemic embolism compared with warfarin, according to a recent subset analysis of a major clinical trial.

Stroke is the third-leading cause of death in India; approximately 145 out of every 100,000 Indians experienced a stroke between 2005 and 2006, according to a 2010 study. Complications of stoke include death, disabilities such as cognitive and/or physical decline, seizures, dementia, and depression.

In the recently published study of apixaban, researchers at the Department of Neurology at the University of California-San Francisco in San Francisco, California, United States, conducted an analysis of a subset of patients that participated in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial to determine the...